Algert Global LLC Athira Pharma, Inc. Transaction History

Algert Global LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.24 - $4.15 $32,972 - $61,088	14,720 New	14,720 $40,000
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $23,812 - $36,223	-10,090 Reduced 26.65%	27,770 $82,000
Q1 2023 May 12, 2023	BUY	$2.26 - $4.22 $6,034 - $11,267	2,670 Added 7.59%	37,860 $95,000
Q3 2022 Nov 15, 2022	BUY	$2.93 - $3.96 $103,106 - $139,352	35,190 New	35,190 $105,000
Q4 2021 Feb 14, 2022	SELL	$9.17 - $16.39 $170,617 - $304,952	-18,606 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$9.15 - $11.09 $170,244 - $206,340	18,606 New	18,606 $175,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $19.7M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.